Irbesartán/Hidroclorotiazida Combix (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartán/Hidroclorotiazida Combix, is an angiotensin II receptor blocker and thiazide diuretic presented as a tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Irbesartán/Hidroclorotiazida Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Its export network covers Europe, Asia, Africa and the Americas, ensuring reliable access to the medication.

Irbesartan/Hydrochlorothiazide is indicated for hypertension, acting on the renin‑angiotensin system and renal sodium handling.

- Hypertension: reduces systolic and diastolic blood pressure, helping achieve target levels. - Essential hypertension: provides consistent blood pressure control in patients with primary hypertension. - Secondary hypertension: assists in managing blood pressure when caused by renal or endocrine disorders.

The combination may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Increased urination. - Electrolyte disturbances such as low potassium. - Fatigue. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance. - Acute kidney injury or worsening renal function. - Hyperkalemia leading to cardiac arrhythmia. - Allergic reactions including rash, angioedema, or anaphylaxis. - Severe hypotension causing fainting. - Hepatic dysfunction with jaundice.

Before initiating therapy, clinicians should consider several safety aspects.

- Renal function: monitor serum creatinine and eGFR regularly. - Electrolytes: check potassium and sodium levels periodically. - Pregnancy: contraindicated in pregnancy (Category D) due to fetal risk. - Elderly: start at lower dose and monitor for orthostatic hypotension. - Drug interactions: review concomitant medications for additive effects. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Irbesartan/Hydrochlorothiazide can interact with several drug classes; awareness helps avoid adverse outcomes.

Major Interactions (Avoid): - ACE inhibitors: increased risk of hyperkalemia and renal impairment. - Potassium‑sparing diuretics: may cause dangerous hyperkalemia. - Lithium: concurrent use can raise lithium levels and toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Other antihypertensives: additive hypotensive effect requires dose adjustment. - CYP2C9 inhibitors (e.g., fluconazole): can raise irbesartan plasma concentrations.